Audit committees roles in biotech firms

Introduction

Audit committees play an essential role in ensuring financial transparency, corporate governance, regulatory compliance and accountability within biotechnology companies. Biotech firms operate in a highly specialised industry involving scientific research, pharmaceutical manufacturing, clinical trials, genetic engineering, biological products and intellectual property development. These activities create financial, operational, ethical and regulatory risks that require effective internal supervision.

An audit committee is a specialised committee of a company's board of directors responsible for overseeing financial reporting, internal control systems, statutory audits and compliance with applicable laws. In biotechnology companies, its responsibilities extend beyond conventional financial supervision because the industry involves research expenditure, clinical trial investments, product safety obligations, biosafety requirements and complex intellectual property arrangements.

In India, the legal framework governing audit committees is primarily established under the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and applicable accounting and auditing standards.

Meaning and importance of audit committees in biotechnology firms

An audit committee is a board-level committee established to independently supervise financial reporting, auditing procedures and internal control mechanisms.

Biotechnology companies frequently undertake expensive and long-term research projects before commercialising their products. They may also receive government grants, enter international licensing agreements and collaborate with universities, pharmaceutical companies and research institutions.

These activities create several governance challenges, including:

Financial mismanagement of research and development funds.

Improper recognition of research and development expenditure.

Misrepresentation of clinical trial results or commercial prospects.

Conflicts of interest involving directors and research partners.

Non-compliance with pharmaceutical and environmental regulations.

Misuse of intellectual property and licensing arrangements.

Fraudulent financial reporting and inaccurate disclosures.

Audit committees help address these concerns by ensuring that management decisions remain transparent, accountable and consistent with applicable legal requirements.

Legal framework governing audit committees in India

1. Companies Act, 2013

The Companies Act, 2013 establishes the principal statutory framework for audit committees in Indian companies.

Section 177 – Audit Committee

Section 177 requires prescribed classes of companies to constitute an audit committee.

The committee generally consists of at least three directors, with independent directors forming a majority.

Its responsibilities include:

Recommending the appointment and remuneration of auditors.

Reviewing auditor independence and performance.

Examining financial statements and audit reports.

Approving or modifying transactions with related parties.

Evaluating internal financial controls and risk management systems.

Monitoring the use of funds raised through public offers.

Reviewing compliance with applicable financial reporting requirements.

For biotechnology companies, these responsibilities are particularly important because research expenditure, clinical development costs and technology licensing transactions can involve substantial financial commitments.

Section 134 – Financial statements and board reports

Section 134 requires companies to prepare financial statements and board reports in accordance with applicable statutory requirements.

The audit committee supports the reliability of financial disclosures by examining financial reporting systems and identifying material irregularities.

Section 143 – Powers and duties of auditors

Section 143 establishes the statutory duties and powers of auditors, including access to books, accounts and relevant records.

The audit committee works alongside statutory auditors to ensure that financial irregularities and significant compliance concerns receive appropriate attention.

Section 188 – Related party transactions

Section 188 regulates specified related party transactions.

Biotechnology companies frequently enter into research collaborations, technology licensing agreements and service arrangements with related entities.

The audit committee must ensure that applicable approval, disclosure and governance requirements are followed.

2. SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Listed biotechnology companies must comply with applicable SEBI corporate governance requirements.

Regulation 18 governs the composition and functioning of audit committees.

The committee must generally consist of at least three directors, with at least two-thirds being independent directors.

Its responsibilities include reviewing financial information, related party transactions, internal audit reports, risk management systems and compliance matters.

Regulation 23 also establishes requirements concerning related party transactions.

These provisions help protect shareholders and strengthen financial accountability in listed biotechnology companies.

3. Companies (Accounts) Rules, 2014

These Rules establish requirements concerning the preparation and maintenance of company accounts and financial records.

Biotechnology companies must maintain accurate records relating to research expenditure, laboratory assets, manufacturing equipment, grants and other financial activities.

The audit committee may examine whether appropriate internal accounting systems are maintained.

4. Companies (Auditor's Report) Order, 2020

The Companies (Auditor's Report) Order, 2020 (CARO 2020) establishes additional reporting requirements for auditors of companies covered by the Order.

It addresses matters such as fixed assets, inventory, loans, statutory dues, fraud and internal audit systems.

For biotechnology firms, these requirements are relevant to expensive laboratory infrastructure, manufacturing facilities, equipment and financial obligations.

Major roles and responsibilities of audit committees in biotech firms

1. Financial reporting and transparency

One of the primary responsibilities of an audit committee is ensuring the accuracy and reliability of financial statements.

Biotechnology firms often invest substantial amounts in research and development before generating commercial revenue.

The committee should examine:

Research and development expenditure.

Capitalisation of eligible development costs.

Revenue recognition from licensing agreements.

Government research grants and subsidies.

Clinical development expenses.

Valuation of intangible assets.

This supervision helps prevent misleading financial statements and protects investors.

2. Monitoring research and development expenditure

Research and development activities are central to biotechnology businesses.

A company may spend several years developing a vaccine, biosimilar, diagnostic product or genetically engineered technology before commercialisation.

The audit committee should ensure that research expenditure is accurately recorded and supported by appropriate documentation.

It should also examine whether management's financial assumptions concerning ongoing research projects are reasonable.

However, scientific decisions and experimental conclusions remain primarily the responsibility of qualified scientific and operational teams.

3. Regulatory compliance and biosafety oversight

Biotechnology firms operate under various regulatory frameworks concerning biological products, clinical trials, environmental protection and manufacturing standards.

The audit committee should review whether appropriate compliance-monitoring systems exist for applicable requirements under:

Drugs and Cosmetics Act, 1940.

New Drugs and Clinical Trials Rules, 2019.

Environment (Protection) Act, 1986.

Rules of 1989 concerning specified genetically engineered organisms and hazardous microorganisms.

Biological Diversity Act, 2002.

The committee should receive reports concerning material regulatory violations, penalties, compliance failures and potential financial liabilities.

4. Internal audit and risk management

Biotechnology companies face specialised risks involving research funding, product development, manufacturing quality, intellectual property and regulatory approvals.

The audit committee must evaluate whether internal audit systems adequately address these risks.

Important areas include financial fraud prevention, procurement controls, laboratory asset management, inventory monitoring and contract compliance.

It should also examine whether management has implemented corrective measures for identified weaknesses.

5. Clinical trial financial oversight

Clinical trials require substantial financial resources and involve multiple research institutions, hospitals, investigators and service providers.

The audit committee should review financial controls relating to clinical research contracts, trial-related payments, research grants and external service providers.

It should also examine whether material regulatory and ethical compliance concerns are appropriately reported to the board.

Scientific assessment of trial safety and participant protection remains the responsibility of the relevant medical, ethics and regulatory authorities.

6. Intellectual property and licensing supervision

Biotechnology firms frequently generate valuable intellectual property through patents, research collaborations and proprietary technologies.

The audit committee should review the financial and accounting treatment of:

Patent acquisition and maintenance expenses.

Technology transfer agreements.

Royalty payments.

Licensing income.

Research collaboration agreements.

Intangible asset valuations.

This helps ensure that intellectual property transactions are properly documented and financial interests are protected.

7. Prevention of fraud and conflicts of interest

Biotechnology companies may enter into transactions with directors, promoters, research partners and associated entities.

The audit committee must monitor related party transactions and ensure that applicable approval and disclosure requirements are followed.

It should also establish appropriate mechanisms for investigating suspected financial misconduct.

Important case laws and judicial principles

1. Satyam Computer Services Ltd. v. Union of India (2009)

The Satyam corporate fraud scandal exposed serious weaknesses in financial reporting, auditing and corporate governance.

The proceedings highlighted the importance of independent supervision, accurate financial statements and effective internal controls.

Legal principle: Corporate governance mechanisms must ensure financial transparency and accountability.

Relevance: Biotechnology firms managing substantial research investments and external funding require effective audit committees to identify financial irregularities and protect shareholders.

2. Dale and Carrington Investment (P) Ltd. v. P.K. Prathapan (2005)

The Supreme Court examined directors' fiduciary duties and their obligation to act in the interests of the company.

The Court emphasised that directors must exercise their powers honestly and for legitimate corporate purposes.

Legal principle: Directors must act in good faith and cannot misuse corporate powers for personal benefit.

Relevance: Audit committees in biotechnology companies must scrutinise transactions involving promoters, directors and related research or commercial entities.

3. N. Narayanan v. Adjudicating Officer, SEBI (2013)

The Supreme Court considered corporate disclosure obligations and the responsibilities of persons involved in company management.

The judgment emphasised the importance of truthful financial disclosures and accountability in corporate governance.

Legal principle: Directors and responsible corporate officers must ensure that financial statements and disclosures are not misleading.

Relevance: This principle is important for biotechnology companies disclosing research expenditure, commercial performance, licensing income and financial risks to investors.

4. Official Liquidator v. P.A. Tendolkar (1973)

The Supreme Court examined the responsibilities and potential liability of company directors in circumstances involving corporate misconduct.

The decision recognised that directors cannot automatically avoid responsibility where their conduct, knowledge or failure to discharge relevant duties establishes legal accountability.

Legal principle: Directors may be held responsible where their conduct or legally relevant neglect contributes to corporate wrongdoing.

Relevance: Audit committee members must exercise appropriate diligence while performing their statutory responsibilities.

5. Tata Consultancy Services Ltd. v. Cyrus Investments Pvt. Ltd. (2021)

The Supreme Court examined corporate governance, board powers and the legal principles governing oppression and mismanagement under company law.

The judgment discussed the importance of respecting the statutory framework governing corporate decision-making.

Legal principle: Corporate governance disputes must be examined within the applicable statutory framework, and courts do not ordinarily substitute their views for legitimate business decisions.

Relevance: The decision provides broader guidance concerning board accountability and governance structures in biotechnology companies.

Challenges faced by audit committees in biotechnology firms

Audit committees in biotechnology companies encounter several industry-specific difficulties.

1. Complex financial structures: Biotechnology firms may receive funding through venture capital, government grants, research partnerships and international collaborations.

2. Long research cycles: Research projects may continue for several years without producing immediate commercial revenue.

3. Regulatory uncertainty: Changes in pharmaceutical, environmental and biotechnology regulations may create additional financial liabilities.

4. Intellectual property valuation: Determining the commercial value of patents, biological processes and research technologies can be difficult.

5. Scientific complexity: Audit committee members may require specialist advice to understand the financial implications of complex biotechnology projects.

6. International compliance: Companies operating across different countries must manage varying accounting, taxation, pharmaceutical and corporate governance requirements.

Recommendations for effective audit committee governance

An effective audit committee in a biotechnology company should:

Maintain a majority of independent directors where required by law.

Ensure that at least one member possesses appropriate financial expertise.

Conduct regular reviews of financial statements and internal audit reports.

Monitor research and development expenditure.

Review material regulatory violations and compliance risks.

Examine related party transactions and licensing agreements.

Strengthen fraud prevention and whistleblower mechanisms.

Monitor financial risks associated with clinical research and manufacturing.

Obtain specialist advice on complex biotechnology transactions.

Ensure transparent reporting to shareholders and regulatory authorities.

Conclusion

Audit committees play a fundamental role in maintaining corporate governance, financial accountability and regulatory compliance in biotechnology firms. Their responsibilities are particularly significant because biotechnology companies operate in a research-intensive and highly regulated business environment involving substantial investments, clinical trials, intellectual property and biological manufacturing.

In India, Section 177 of the Companies Act, 2013, and Regulation 18 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, provide the principal legal framework governing audit committees.

Judicial decisions such as Satyam Computer Services Ltd. v. Union of India, Dale and Carrington Investment v. P.K. Prathapan and N. Narayanan v. SEBI establish important principles concerning financial transparency, directors' duties and corporate accountability.

Ultimately, an effective audit committee must ensure that biotechnology companies maintain reliable financial records, comply with applicable regulations, manage corporate risks and protect shareholder interests. Strong audit committee governance is therefore essential for building investor confidence and promoting sustainable growth in India's biotechnology industry.